Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000662418 | SCV000784854 | uncertain significance | Colorectal cancer, susceptibility to, 12 | 2017-01-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001027015 | SCV001189503 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-07-26 | criteria provided, single submitter | clinical testing | The p.R266* variant (also known as c.796C>T), located in coding exon 8 of the POLE gene, results from a C to T substitution at nucleotide position 796. This changes the amino acid from an arginine to a stop codon within coding exon 8. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. However, loss of function via haploinsufficiency in POLE has not been clearly established as a mechanism of disease. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003656649 | SCV001517950 | pathogenic | not provided | 2023-07-12 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 548720). This variant has not been reported in the literature in individuals affected with POLE-related conditions. This variant is present in population databases (rs767666219, gnomAD 0.006%). This sequence change creates a premature translational stop signal (p.Arg266*) in the POLE gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in POLE are known to be pathogenic (PMID: 23230001, 25948378, 30503519). |